Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOVON phase III trial of VMP versus HDM/ASCT with optional VRD consolidation in newly diagnosed multiple myeloma
NL-OMON54491Phase 3Completed
- Sponsor
- HOVON
- Start
- Jan 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bortezomib, melphalan, prednisone, lenalidomide, dexamethasone and 1 more in multiple myeloma (MM) (5 arms), sponsored by HOVON. Primary endpoints: Progression-free survival from registration, Progression-free survival from randomization R1 and 1 more. Started Jan 2011; status: completed.
02
Drugs
bortezomibmelphalanprednisonelenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON54491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54491.